National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Abrocitinib (Cibinqo®) HTA ID: 21056

Abrocitinib (Cibinqo®) is indicated for the treatment of moderate-to-severe atopic dermatitis in adults aged 18 years and older who are candidates for systemic therapy.

NCPE Assessment Process Complete
Rapid review commissioned 16/11/2021
Rapid review completed 23/12/2021
Rapid Review outcome A full HTA is not recommended. The NCPE recommends that abrocitinib not be considered for reimbursement at the submitted price*.

 

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.